Literature DB >> 25521356

Genotype and risk of major bleeding during warfarin treatment.

Vivian K Kawai1, Andrew Cunningham, Susan I Vear, Sara L Van Driest, Abimbola Oginni, Hua Xu, Min Jiang, Chun Li, Joshua C Denny, Christian Shaffer, Erica Bowton, Brian F Gage, Wayne A Ray, Dan M Roden, C Michael Stein.   

Abstract

AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. MATERIALS &
METHODS: Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy.
RESULTS: CYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04).
CONCLUSION: The CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.

Entities:  

Keywords:  CYP2C9; CYP4F2; VKORC1; pharmacogenetics; risk of major bleeding; warfarin

Mesh:

Substances:

Year:  2014        PMID: 25521356      PMCID: PMC4304738          DOI: 10.2217/pgs.14.153

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  42 in total

Review 1.  Guidelines on oral anticoagulation with warfarin - fourth edition.

Authors:  David Keeling; Trevor Baglin; Campbell Tait; Henry Watson; David Perry; Caroline Baglin; Steve Kitchen; Michael Makris
Journal:  Br J Haematol       Date:  2011-06-14       Impact factor: 6.998

2.  Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

Authors:  J A Roth; D Boudreau; M M Fujii; F M Farin; A E Rettie; K E Thummel; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2014-02-06       Impact factor: 6.875

3.  Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.

Authors:  Benjamin D Horne; Petra A Lenzini; Mia Wadelius; Andrea L Jorgensen; Stephen E Kimmel; Paul M Ridker; Niclas Eriksson; Jeffrey L Anderson; Munir Pirmohamed; Nita A Limdi; Robert C Pendleton; Gwendolyn A McMillin; James K Burmester; Daniel Kurnik; C Michael Stein; Michael D Caldwell; Charles S Eby; Anders Rane; Jonatan D Lindh; Jae-Gook Shin; Ho-Sook Kim; Pantep Angchaisuksiri; Robert J Glynn; Kathryn E Kronquist; John F Carlquist; Gloria R Grice; Robert L Barrack; Juan Li; Brian F Gage
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

4.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

5.  Interindividual variability in sensitivity to warfarin--Nature or nurture?

Authors:  R Loebstein; H Yonath; D Peleg; S Almog; M Rotenberg; A Lubetsky; J Roitelman; D Harats; H Halkin; D Ezra
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

6.  Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Authors:  Andrea H Ramirez; Yaping Shi; Jonathan S Schildcrout; Jessica T Delaney; Hua Xu; Matthew T Oetjens; Rebecca L Zuvich; Melissa A Basford; Erica Bowton; Min Jiang; Peter Speltz; Raquel Zink; James Cowan; Jill M Pulley; Marylyn D Ritchie; Daniel R Masys; Dan M Roden; Dana C Crawford; Joshua C Denny
Journal:  Pharmacogenomics       Date:  2012-02-13       Impact factor: 2.533

Review 7.  Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.

Authors:  Jie Yang; Yanming Chen; Xiaoqi Li; Xiaowen Wei; Xi Chen; Lanning Zhang; Yuxiao Zhang; Qiang Xu; Hongjuan Wang; Yang Li; Caiyi Lu; Wei Chen; Changqing Zeng; Tong Yin
Journal:  Int J Cardiol       Date:  2013-08-07       Impact factor: 4.164

8.  National trends in oral anticoagulant use in the United States, 2007 to 2011.

Authors:  Kate Kirley; Dima M Qato; Rachel Kornfield; Randall S Stafford; G Caleb Alexander
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-09-04

9.  Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.

Authors:  Kirstin Lund; Dairena Gaffney; Richard Spooner; Anne Marie Etherington; Patrick Tansey; Robert Campbell Tait
Journal:  Br J Haematol       Date:  2012-05-10       Impact factor: 6.998

10.  A randomized trial of genotype-guided dosing of warfarin.

Authors:  Munir Pirmohamed; Girvan Burnside; Niclas Eriksson; Andrea L Jorgensen; Cheng Hock Toh; Toby Nicholson; Patrick Kesteven; Christina Christersson; Bengt Wahlström; Christina Stafberg; J Eunice Zhang; Julian B Leathart; Hugo Kohnke; Anke H Maitland-van der Zee; Paula R Williamson; Ann K Daly; Peter Avery; Farhad Kamali; Mia Wadelius
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more
  25 in total

1.  Genetic determinants of variability in warfarin response after the dose-titration phase.

Authors:  Otito F Iwuchukwu; Andrea H Ramirez; Yaping Shi; Erica A Bowton; Vivian K Kawai; Jonathan S Schildcrout; Dan M Roden; Joshua C Denny; C Michael Stein
Journal:  Pharmacogenet Genomics       Date:  2016-11       Impact factor: 2.089

2.  Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.

Authors:  Nita A Limdi; Todd M Brown; Aditi Shendre; Nianjun Liu; Charles E Hill; Timothy M Beasley
Journal:  Pharmacogenet Genomics       Date:  2017-10       Impact factor: 2.089

3.  Pharmacogenetic Implementation Lessons From the "Real World".

Authors:  D M Roden
Journal:  Clin Pharmacol Ther       Date:  2017-03-25       Impact factor: 6.875

Review 4.  Phenome-Wide Association Studies as a Tool to Advance Precision Medicine.

Authors:  Joshua C Denny; Lisa Bastarache; Dan M Roden
Journal:  Annu Rev Genomics Hum Genet       Date:  2016-05-04       Impact factor: 8.929

5.  The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development.

Authors:  Joshua C Denny; Sara L Van Driest; Wei-Qi Wei; Dan M Roden
Journal:  Clin Pharmacol Ther       Date:  2018-02-05       Impact factor: 6.875

6.  Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review.

Authors:  Xiang-Min Shi; Fu-Kun Chen; Zhuo Liang; Jian Li; Kun Lin; Jian-Ping Guo; Zhao-Liang Shan
Journal:  Int J Clin Exp Med       Date:  2015-04-15

7.  Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention.

Authors:  Eitan A Friedman; Luisa Texeira; Jessica Delaney; Peter E Weeke; Donald R Lynch; Ehab Kasasbeh; Yanna Song; Frank E Harrell; Josh C Denny; Heidi E Hamm; Dan M Roden; John H Cleator
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

8.  Integrating electronic health record genotype and phenotype datasets to transform patient care.

Authors:  D M Roden; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2016-01-26       Impact factor: 6.875

9.  Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.

Authors:  Innocent G Asiimwe; Eunice J Zhang; Rostam Osanlou; Amanda Krause; Chrisly Dillon; Guilherme Suarez-Kurtz; Honghong Zhang; Jamila A Perini; Jessicca Y Renta; Jorge Duconge; Larisa H Cavallari; Leiliane R Marcatto; Mark T Beasly; Minoli A Perera; Nita A Limdi; Paulo C J L Santos; Stephen E Kimmel; Steven A Lubitz; Stuart A Scott; Vivian K Kawai; Andrea L Jorgensen; Munir Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2020-01-28       Impact factor: 6.875

10.  Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.

Authors:  Marwa Ajmi; Asma Omezzine; Slim Achour; Dorra Amor; Haithem Hamdouni; Fatma Ben Fredj Ismaïl; Nabila Ben Rejeb; Chedia Laouani Kechrid; Essia Boughzela; Ali Bouslama
Journal:  Eur J Clin Pharmacol       Date:  2018-02-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.